Expression data from doxorubicin-resistant hepatoma cells. Expression data from doxorubicin-resistant hepatoma cells

Transarterial chemoembolization or systemic chemotherapy with doxorubicin has been the treatment of choice for unresectable hepatocellular carcinoma (HCC) conferring the best survival benefit. However, HCC is notorious for its predisposition to develop therapeutic tolerance. Thus, Affymetrix microarray analysis was performed on doxorubicin-resistant hepatoma cells to identify the drug resistance-related genes. The RNA isolated from primary hepatoma cells and their doxorubicin-resistant counterparts, then subjected to Affymetrix microarray analysis to identify the differential expression profiles of drug resistance-related genes. Overall design: We used Affymetrix microarrays to detail the global gene expression of primary cells, including 834, 413, and P15 as well as their resistant counterparts to identify the differential expression profiles of drug resistance-related genes.